Search details
1.
Randomized phase II study of weekly carfilzomib 70 mg/m2 and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients.
Haematologica
; 108(10): 2753-2763, 2023 10 01.
Article
in English
| MEDLINE | ID: mdl-37102598
2.
A research center's experience of T-cell redirecting therapies in triple-class refractory multiple myeloma.
Blood Adv
; 2024 May 08.
Article
in English
| MEDLINE | ID: mdl-38717869
3.
[Monoclonal gammopathy of uncertain significance]. / Gammapatía monoclonal de significado incierto.
Med Clin (Barc)
; 161(5): 217-224, 2023 09 08.
Article
in English, Spanish
| MEDLINE | ID: mdl-37330390
4.
Multiple myeloma with t(11;14): impact of novel agents on outcome.
Blood Cancer J
; 13(1): 40, 2023 03 20.
Article
in English
| MEDLINE | ID: mdl-36935422
5.
Novel Agents as Main Drivers for Continued Improvement in Survival in Multiple Myeloma.
Cancers (Basel)
; 15(5)2023 Mar 02.
Article
in English
| MEDLINE | ID: mdl-36900349
6.
Anti-BCMA CAR T-cell Therapy: Changing the Natural History of Multiple Myeloma.
Hemasphere
; 6(3): e691, 2022 Mar.
Article
in English
| MEDLINE | ID: mdl-35187407
7.
Gammapatía monoclonal de significado incierto / Monoclonal gammopathy of uncertain significance
Med. clín (Ed. impr.)
; 161(5): 217-224, sept. 2023.
Article
in Spanish
| IBECS (Spain) | ID: ibc-224739
Results
1 -
7
de 7
1
Next >
>>